Larimar Therapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 4 | -$0.31 | -$0.31 | -$0.31 |
Q2 2024 | 3 | -$0.37 | -$0.37 | -$0.37 |
Q3 2024 | 8 | -$0.35 | -$0.30 | -$0.32 |
Q1 2025 | 4 | -$0.41 | -$0.28 | -$0.35 |
Q2 2025 | 2 | -$0.39 | -$0.39 | -$0.39 |
Q3 2025 | 2 | -$0.43 | -$0.43 | -$0.43 |
Q4 2025 | 2 | -$0.46 | -$0.46 | -$0.46 |
Q1 2026 | 1 | -$0.43 | -$0.43 | -$0.43 |
Q2 2026 | 1 | -$0.43 | -$0.43 | -$0.43 |
Q3 2026 | 1 | -$0.43 | -$0.43 | -$0.43 |
Q4 2026 | 1 | -$0.44 | -$0.44 | -$0.44 |
Larimar Therapeutics, Inc. Earnings Date And Information
Larimar Therapeutics, Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $-0.24 earnings per share for the quarter, topping analysts' consensus estimates of $-0.37 by $0.13. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Larimar Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.84 diluted earnings per share) and currently has a price-to-earnings ratio of -7.3. Larimar Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.
Larimar Therapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/30/2024 | Q3 2024 | -$0.37 | -$0.24 | 0.13 | $0 | $0 |
08/08/2024 | Q2 2024 | -$0.34 | $0 | $0 | ||
03/29/2024 | Q1 2024 | -$0.27 | $0 | |||
12/30/2023 | Q4 2023 | -$0.30 | $0 | |||
11/14/2023 | Q3 2023 | -$0.23 | -$0.21 | 0.02 | $0 | |
08/10/2023 | Q2 2023 | -$0.21 | -$0.19 | 0.02 | $0 | |
05/15/2023 | Q1 2023 | -$0.12 | $0 | |||
03/14/2023 | Q4 2022 | -$0.78 | -$0.35 | 0.43 | $0 | |
11/10/2022 | Q3 2022 | -$0.50 | -$0.37 | 0.13 | $0 | |
08/11/2022 | Q2 2022 | -$0.62 | -$0.47 | 0.15 | $0 | |
05/12/2022 | Q1 2022 | -$0.62 | -$0.49 | 0.13 | $0 | |
03/25/2022 | Q4 2021 | -$0.50 | $0 | |||
11/12/2021 | Q3 2021 | -$0.62 | -$0.92 | -0.3 | $0 | |
08/12/2021 | Q2 2021 | -$0.73 | -$0.79 | -0.06 | $0 | |
05/10/2021 | Q1 2021 | -$0.93 | -$0.76 | 0.17 | $0 | |
03/04/2021 | Q4 2020 | -$0.72 | -$0.89 | -0.17 | $0 | |
11/12/2020 | Q3 2020 | -$0.64 | $0 | |||
08/14/2020 | Q2 2020 | -$1.21 | $0 | |||
05/07/2020 | Q1 2020 | -$0.72 | $0 | |||
03/05/2020 | Q4 2019 | -$2.28 | -$0.66 | 1.62 | $0 |
Larimar Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Larimar Therapeutics, Inc.'s earnings date?
Larimar Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based off last year's report dates.
-
Did Larimar Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Larimar Therapeutics, Inc. (:LRMR) reported $-0.24 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.37 by $0.13.
-
How can I listen to Larimar Therapeutics, Inc.'s earnings conference call?
The conference call for Larimar Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Larimar Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Larimar Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Larimar Therapeutics, Inc. generate each year?
Larimar Therapeutics, Inc. (:LRMR) has a recorded net income of $0. Larimar Therapeutics, Inc. has generated $-0.84 earnings per share over the last four quarters.
-
What is Larimar Therapeutics, Inc.'s price-to-earnings ratio?
Larimar Therapeutics, Inc. (:LRMR) has a price-to-earnings ratio of -7.3 and price/earnings-to-growth ratio is -0.39.